Market open
Seres Therapeutics/$MCRB
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Seres Therapeutics
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
Ticker
$MCRB
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
233
Website
MCRB Metrics
BasicAdvanced
$122M
Market cap
-
P/E ratio
-$1.17
EPS
1.96
Beta
-
Dividend rate
Price and volume
Market cap
$122M
Beta
1.96
52-week high
$2.05
52-week low
$0.54
Average daily volume
3.2M
Financial strength
Current ratio
1.378
Quick ratio
0.83
Long term debt to equity
-233.629
Total debt to equity
-244.189
Interest coverage (TTM)
-9.77%
Management effectiveness
Return on assets (TTM)
-27.10%
Return on equity (TTM)
502.96%
Valuation
Price to revenue (TTM)
265.874
Price to book
-1.25
Price to tangible book (TTM)
-1.25
Price to free cash flow (TTM)
-0.538
Growth
Revenue change (TTM)
-99.71%
Earnings per share change (TTM)
-4.34%
3-year revenue growth (CAGR)
-76.80%
3-year earnings per share growth (CAGR)
-7.47%
What the Analysts think about MCRB
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Seres Therapeutics stock.
MCRB Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
MCRB Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
MCRB News
AllArticlesVideos
Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024
GlobeNewsWire·2 days ago
Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A
GlobeNewsWire·1 month ago
Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestlé
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Seres Therapeutics stock?
Seres Therapeutics (MCRB) has a market cap of $122M as of November 08, 2024.
What is the P/E ratio for Seres Therapeutics stock?
The price to earnings (P/E) ratio for Seres Therapeutics (MCRB) stock is 0 as of November 08, 2024.
Does Seres Therapeutics stock pay dividends?
No, Seres Therapeutics (MCRB) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next Seres Therapeutics dividend payment date?
Seres Therapeutics (MCRB) stock does not pay dividends to its shareholders.
What is the beta indicator for Seres Therapeutics?
Seres Therapeutics (MCRB) has a beta rating of 1.96. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.